Carrier Screen

Foresight® product signature

The Foresight® Carrier Screen can help determine whether you carry inherited health conditions that you might pass on to a child. Knowing this information before you get pregnant, or early in your pregnancy, can make a difference in your family’s well-being.

Learn more

The Foresight® Carrier Screen can help determine whether you carry inherited health conditions that you might pass on to a child. Knowing this information before you get pregnant, or early in your pregnancy, can make a difference in your family’s well-being.

Learn more

Germline Tests

BRACAnalysis CDx product signature

BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).1,2,3

Learn more

BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).1,2,3

Learn more

MyRisk™ product signature

MyRisk Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.

Learn more

MyRisk Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.

Learn more

Pharmacogenomics Test

GeneSight® product signature

GeneSight® is a pharmacogenomics test that is clinically proven to improve medication selection when used by healthcare providers. GeneSight analyzes how an individual’s genetic variations affect his or her response to medications and provides an actionable, easy to interpret report. GeneSight is used by healthcare providers to help patients diagnosed with depression.

Learn more

GeneSight® is a pharmacogenomics test that is clinically proven to improve medication selection when used by healthcare providers. GeneSight analyzes how an individual’s genetic variations affect his or her response to medications and provides an actionable, easy to interpret report. GeneSight is used by healthcare providers to help patients diagnosed with depression.

Learn more

Prenatal Screen

Prequel® product signature

The Prequel® Prenatal Screen is a non-invasive test that you can take as early as 10 weeks into your pregnancy to learn about your baby’s chance to have a chromosome condition like Down syndrome.

Learn more

The Prequel® Prenatal Screen is a non-invasive test that you can take as early as 10 weeks into your pregnancy to learn about your baby’s chance to have a chromosome condition like Down syndrome.

Learn more

Somatic Tests

Precise™ Tumor product signature

Precise Tumor is a next-generation sequencing (NGS) assay with hybrid capture model consisting of DNA- and RNA-based testing which detects Single-Nucleotide Variants (SNV), Insertion-Deletion Mutations (INDELs), Copy Number Variants (CNV), and fusions in solid tumors.

Learn more

Precise Tumor is a next-generation sequencing (NGS) assay with hybrid capture model consisting of DNA- and RNA-based testing which detects Single-Nucleotide Variants (SNV), Insertion-Deletion Mutations (INDELs), Copy Number Variants (CNV), and fusions in solid tumors.

Learn more

MyChoice® CDx product signature

MyChoice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status.

Learn more

MyChoice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status.

Learn more

Prolaris® product signature

Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.

Learn more

Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.

Learn more

EndoPredict product signature

Making a decision on treatment options for patients diagnosed with early-stage breast cancer is an important choice and one that should be made with the best information possible. EndoPredict® can help accurately determine an individual patient’s 10-year risk of recurrence to help physicians identify which patients may consider safely forgoing chemotherapy.

Learn more

Making a decision on treatment options for patients diagnosed with early-stage breast cancer is an important choice and one that should be made with the best information possible. EndoPredict® can help accurately determine an individual patient’s 10-year risk of recurrence to help physicians identify which patients may consider safely forgoing chemotherapy.

Learn more

No results found for

Please try changing the search criteria, or reset filters